Nanobac Pharmaceuticals, Incorporated (NNBP)

Nanobac Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2007	FY 2006	FY 2005	FY 2004	FY 2003
Period Ending	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005	Dec 31, 2004	Dec 31, 2003
Net Income	-6.58	-4.97	-3.69	-8.52	-3.7
Depreciation & Amortization	0.46	0.54	0.76	0.72	0.18
Loss (Gain) From Sale of Assets	-	0.02	0	-	0.01
Asset Writedown & Restructuring Costs	-	0.59	-	-	-
Stock-Based Compensation	1.71	0.67	0.01	2.56	0.78
Other Operating Activities	1.74	0.24	0.79	0.88	-
Change in Accounts Receivable	-0	0	0	0	0.01
Change in Inventory	0.06	0.05	-0.05	-0.05	0.07
Change in Accounts Payable	0.67	0.09	-0.33	0.53	0.28
Change in Unearned Revenue	-	-0.02	0.01	0.02	-
Change in Other Net Operating Assets	1.03	0.21	0.13	0.47	0.22
Operating Cash Flow	-0.91	-2.58	-2.37	-3.4	-2.16
Capital Expenditures	-0	-0.01	-0.04	-0.04	-0.02
Cash Acquisitions	-	-	-	-0	-0.08
Divestitures	-	-	-	0.2	0.3
Other Investing Activities	0.05	-0	-	0	-0
Investing Cash Flow	0.05	-0.02	-0.04	0.16	0.2
Short-Term Debt Issued	0.91	2.74	2.17	2.07	2
Long-Term Debt Issued	-	-	0.01	0.15	-
Total Debt Issued	0.91	2.74	2.19	2.22	2
Short-Term Debt Repaid	-	-	-	-	-0.04
Long-Term Debt Repaid	-	-0.05	-0.02	-0.18	-0.49
Total Debt Repaid	-	-0.05	-0.02	-0.18	-0.52
Net Debt Issued (Repaid)	0.91	2.69	2.16	2.04	1.47
Issuance of Common Stock	-	-	0.2	1.28	0.55
Other Financing Activities	-	-	-0.04	-0.1	-
Financing Cash Flow	0.91	2.69	2.33	3.22	2.02
Foreign Exchange Rate Adjustments	-0.08	-0.06	0.07	-0.02	-0.02
Net Cash Flow	-0.04	0.03	-0.01	-0.03	0.05
Free Cash Flow	-0.91	-2.6	-2.41	-3.43	-2.17
Free Cash Flow Margin	-5178.02%	-1154.07%	-366.31%	-957.84%	-450.17%
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.02	-0.03
Cash Interest Paid	0	-	0	0.01	0.04
Levered Free Cash Flow	1.03	-1.75	-1.02	-4.36	-0.81
Unlevered Free Cash Flow	1.15	-1.62	-0.98	-4.2	-0.78
Change in Working Capital	1.75	0.34	-0.24	0.96	0.58

Source: S&P Global Market Intelligence. Standard template. Financial Sources.